Review of cannabis use on reproductive health, pregnancy, and fetal outcomes

A recent study published in the American Journal of Obstetrics and Gynecology reviewed cannabis use on reproductive health, pregnancy, and fetal outcomes.

Study: Impact of cannabinoids on pregnancy, reproductive health and offspring outcomes. Image Credit: Yarygin/Shutterstock
Study: Impact of cannabinoids on pregnancy, reproductive health and offspring outcomes. Image Credit: Yarygin/Shutterstock


Cannabis, a federally illegal drug, is the most consumed drug in the United States (US). Its consumption is increasing worldwide partly due to legalization in several regions and growing social acceptability and accessibility. Cannabis use has been increasing, particularly among individuals of reproductive age. The elevated consumption of cannabis during the coronavirus disease 2019 (COVID-19) pandemic may partly be attributed to increased stress and anxiety.

The endocannabinoid system mediates the biological effects of cannabis. Endocannabinoid receptor expression has been observed in developing fetuses as early as the fifth gestational week. Cannabinoid receptors have been reported in male/female reproductive tracts, sperms, and placenta, indicating that the endocannabinoid system might regulate reproduction. Delta-9-tetrahydrocannabinol (THC), the principal psychoactive element of cannabis, has been detected in breastmilk and could cross the placenta.

Moreover, evidence about the safety of cannabis use, particularly regarding reproductive health and pregnancy, is limited. As such, nearly 70% of US females believe that consuming cannabis once or twice a week is innocuous. Given the increase in cannabis consumption, it is necessary to study the effects/impact of cannabis on reproductive health and developmental outcomes of offspring.

Cannabinoid pharmacology

Cannabis is a member of the Cannabaceae family and has over 80 bioactive chemical compounds, with THC and cannabidiol being the most commonly known. Cannabinoid receptors (CB1 and CB2) are expressed in the central nervous system and peripheral tissues. Some of the therapeutic properties of cannabinoids include muscle relaxation, analgesia, anti-inflammation, immunosuppression, sedation, mood improvement, anti-emesis, and appetite stimulation, among others. Nonetheless, cannabinoids are not approved for therapeutic use.

Cannabis consumption and legalization

Smoking is the most common way of cannabis administration, followed by edibles. Cannabis use disorder (CUD) occurs in about 10% of regular consumers and 50% chronic users. Therapeutic options for CUD are limited and include psychosocial intervention, motivational enhancement therapy, and cognitive behavioral therapy or a combination. Several American, African, European, and Australian regions have decriminalized the use of cannabis.

The significantly increased consumption of cannabis has been due to the legalization of recreational cannabis. In the US, 18 states legalized recreational cannabis in 2021. These legal changes would likely influence cannabis consumption among adolescents and children. It has been suggested that the puberty and mental health of the pediatric population could be impacted by cannabis use.

Cannabis use by males and paternal impact

The effect of chronic consumption of cannabis among men is inconsistent, with reports of minimal-to-no changes in follicle-stimulating hormone (FSH) levels or poorer semen parameters. Animal studies observed that THC exposure could result in adverse effects on spermatogenesis, decrease in gonadotropins, abnormal sperm morphology, and testicular atrophy.

One recent report demonstrated that cannabis exposure in rats and humans was associated with altered methylation of deoxyribonucleic acid (DNA). The affected genes were implicated in cancers and early development, including neurodevelopment.

Impact of Cannabis on female reproductive health, pregnancy, lactation, and fetal outcomes

Various studies suggest that cannabis affects processes associated with female reproductive health, such as ovulation, secretion of luteinizing hormone (LH) and FSH, and menstrual cyclicity. Studies on mice showed that prolactin, FSH, and LH levels were suppressed upon acute THC administration. Women that use cannabis during pregnancy are often involved in polysubstance use resulting in a synergistic or additive effect.

Moreover, half the women who use cannabis continue it throughout the pregnancy. There are growing concerns about adverse fetal/neonatal outcomes since THC could bind to cannabinoid receptors in the placenta or fetal brain. The risk of miscarriage and stillbirth is also higher but is inconsistent across different studies. Some studies suggested higher odds of admissions to neonatal intensive care unit (NICU), small for gestational age (SGA), placenta abruption, and infant deaths.

Impairment of cytotrophoblast fusion and biochemical differentiation by THC has been observed in vitro. Further, THC inhibits migration of the epithelial layer of amnion, affecting its development during the gestational period and contributing to adverse pregnancy outcomes, including preterm labor. Hyperactivity, impulsivity, abnormal visual and verbal reasoning, and attention deficit have been reported in preschool children born to mothers who used THC during pregnancy.

Lactating mothers are likely to increase cannabis use within two months of childbirth. This raises concerns about the gradual release of THC from lipid-filled tissues in the offspring transferred through breastmilk. Furthermore, chronic usage of cannabis increased THC concentration by more than eight times in breastmilk relative to plasma. Newborns with THC exposure within a month of birth have been observed to have reduced motor development.

Concluding remarks

While the use of cannabis is growing, data on its safety, particularly on reproductive health, are limited. The current literature suggests that its use has significant health implications, and it is gravely concerning that 70% of females believe its consumption is safe during pregnancy. Notably, only half the healthcare providers discouraged perinatal cannabis consumption.

Despite the limited safety information, it is critical to have both individuals and healthcare providers informed about the potential adverse effects of cannabis, particularly before conception, during pregnancy, and during the postpartum period.

Journal reference:
Tarun Sai Lomte

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sai Lomte, Tarun. (2022, June 08). Review of cannabis use on reproductive health, pregnancy, and fetal outcomes. News-Medical. Retrieved on March 25, 2023 from

  • MLA

    Sai Lomte, Tarun. "Review of cannabis use on reproductive health, pregnancy, and fetal outcomes". News-Medical. 25 March 2023. <>.

  • Chicago

    Sai Lomte, Tarun. "Review of cannabis use on reproductive health, pregnancy, and fetal outcomes". News-Medical. (accessed March 25, 2023).

  • Harvard

    Sai Lomte, Tarun. 2022. Review of cannabis use on reproductive health, pregnancy, and fetal outcomes. News-Medical, viewed 25 March 2023,


  1. James Tripp James Tripp Canada says:

    Prenatal Marijuana Exposure and Neonatal Outcomes in Jamaica: An Ethnographic Study

    Conclusions. The absence of any differences between the exposed on nonexposed groups in the early neonatal period suggest that the better scores of exposed neonates at 1 month are traceable to the cultural positioning and social and economic characteristics of mothers using marijuana that select for the use of marijuana but also promote neonatal development.

  2. James Tripp James Tripp Canada says:

    Five-year follow-up of rural Jamaican children whose mothers used marijuana during pregnancy


    The results show no significant differences in developmental testing outcomes between children of marijuana-using and non-using mothers except at 30 days of age when the babies of users had more favourable scores on two clusters of the Brazelton Scales

  3. James Tripp James Tripp Canada says:

    endocannabinoids have been detected in maternal milk and activation of CB1 receptors appears to be critical for milk sucking by newborn mice, apparently activating oral–motor musculature. Fourth, anandamide has neuroprotectant properties in the developing postnatal brain.

  4. James Tripp James Tripp Canada says:

    The clinical significance of these findings appears to be limited because cognitive performance scores of cannabis-exposed groups overwhelmingly fell within the normal range when compared against normative data adjusted for age and education.

    Conclusions: The current evidence does not suggest that prenatal cannabis exposure alone is associated with clinically significant cognitive functioning impairments.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Cannabis users have higher complexity of co-existing conditions